<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734197</url>
  </required_header>
  <id_info>
    <org_study_id>C-100-001</org_study_id>
    <nct_id>NCT04734197</nct_id>
  </id_info>
  <brief_title>A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease</brief_title>
  <official_title>A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Surface Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Surface Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an&#xD;
      investigational drug (which means the study drug is currently being tested) in the form of a&#xD;
      sterile eye drop.&#xD;
&#xD;
      The purpose of this research study is to see how well SURF-100 works to treat dry eye and&#xD;
      what potential side effects there are, and to compare it with Vehicle (placebo), 0.1%&#xD;
      mycophenolic acid (MPA) in Vehicle, 0.3% MPA in Vehicle, 0.01% betamethasone phosphate (BSP)&#xD;
      in Vehicle, Restasis and Xiidra. This study will involve about 280-350 study participants age&#xD;
      18 and older at about 40 different research sites in the United States.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UNC DEMS Score</measure>
    <time_frame>Day 84</time_frame>
    <description>A reduction of 10% in patient-reported dry eye disease symptoms and reduction of impact of symptoms on daily life as defined by the University of North Carolina (UNC) Dry Eye Management Scale (DEMS) with SURF-100 as compared to vehicle, RESTASIS and XIIDRA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear Break Up Time (TBUT)</measure>
    <time_frame>Day 84</time_frame>
    <description>Average increase in TBUT compared to vehicle, RESTASIS and XIIDRA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer Tear Test Score</measure>
    <time_frame>Day 84</time_frame>
    <description>Average increase in Schirmer's score test (with anesthesia) compared to vehicle, RESTASIS and XIIDRA.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>SURF-100 (a combination of 0.3% MPA and 0.01% BSP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in the study eye twice daily (BID) for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% MPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in the study eye BID for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% MPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in the study eye BID for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.01% BSP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in the study eye BID for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop in the study eye BID for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop in the study eye BID for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xiidra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop in the study eye BID for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate</intervention_name>
    <description>combination of a topical immunosuppressant and a topical corticosteroid solution</description>
    <arm_group_label>SURF-100 (a combination of 0.3% MPA and 0.01% BSP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>topical vehicle solution</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic Acid 0.1%</intervention_name>
    <description>topical immunosuppressant</description>
    <arm_group_label>0.1% MPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis 0.05% Ophthalmic Emulsion</intervention_name>
    <description>topical ophthalmic emulsion</description>
    <arm_group_label>Restasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiidra 5% Ophthalmic Solution</intervention_name>
    <description>topical ophthalmic solution</description>
    <arm_group_label>Xiidra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic Acid 0.3%</intervention_name>
    <description>topical immunosuppressant</description>
    <arm_group_label>0.3% MPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone Sodium Phosphate 0.01%</intervention_name>
    <description>topical corticosteroid solution</description>
    <arm_group_label>0.01% BSP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults at least 18 years of age at the time of the Screening visit.&#xD;
&#xD;
          2. Willing and able to read, sign, and date the informed consent form (ICF) after the&#xD;
             nature of the study has been explained and any questions have been answered, and prior&#xD;
             to initiation of any study procedures or exams.&#xD;
&#xD;
          3. Willing and able to comply with all study procedures and attend all study visits.&#xD;
&#xD;
          4. Willing to suspend use of tear substitutes at least 72 hours prior to Visit 2 (Day 0)&#xD;
             through Visit 7 (Day 98).&#xD;
&#xD;
          5. Best corrected visual acuity (BCVA) of 0.7 log of the minimum angle of resolution&#xD;
             (logMAR) or better (Snellen equivalent score of 20/100 or better) in each eye at Visit&#xD;
             1 (Day -14 to Day 0).&#xD;
&#xD;
          6. Subject-reported history of dry eye in both eyes.&#xD;
&#xD;
          7. Meeting ALL of the following criteria in the same eye at Visit 1 (Day -14 to Day 0)&#xD;
             and meeting ALL of the following criteria in the same eye at Visit 2 (Day 0) if Visit&#xD;
             2 is performed &gt;5 days after Visit 1:&#xD;
&#xD;
               1. Minimum score of greater than or equal to 5 but less than or equal to 9 on UNC&#xD;
                  DEMS questionnaire.&#xD;
&#xD;
               2. Schirmer Tear Test (with anesthesia) equal to or less than 10 mm, but more than 1&#xD;
                  mm.&#xD;
&#xD;
               3. TBUT: Equal to or less than 5 seconds&#xD;
&#xD;
          8. A negative urine pregnancy test if female and of childbearing potential (those who are&#xD;
             not surgically sterilized [bilateral tubal ligation, hysterectomy, or bilateral&#xD;
             oophorectomy] or post-menopausal [12 months after last menses] or premenarchal) and&#xD;
             must have used adequate birth control throughout the study period (through Visit 7&#xD;
             [Day 98]). Adequate birth control is defined as hormonal-oral, implantable,&#xD;
             injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with&#xD;
             a barrier such as condom or diaphragm; intrauterine device; abstinence; or surgical&#xD;
             sterilization of male partner.&#xD;
&#xD;
          9. Subjects with secondary Sj√∂gren's syndrome (e.g., rheumatoid arthritis, systemic lupus&#xD;
             erythematosus) or other autoimmune diseases (e.g., multiple sclerosis, inflammatory&#xD;
             bowel disease) are eligible for study consideration provided the subject meets all&#xD;
             other inclusion and exclusion criteria, AND are not in a medical state - in the&#xD;
             opinion of the principal investigator - that could interfere with study parameters,&#xD;
             are not taking systemic/ocular steroids, and are not immunodeficient/immunosuppressed&#xD;
             (e.g., receiving systemic immunomodulating or immunosuppressive drugs to manage their&#xD;
             baseline medical state).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications or known hypersensitivity to the study drug(s), including RESTASIS&#xD;
             or XIIDRA, or their components.&#xD;
&#xD;
          2. Subjects who are employees or immediate family members of employees at the&#xD;
             investigational site.&#xD;
&#xD;
          3. Subjects who are members of the same household.&#xD;
&#xD;
          4. Any ocular condition that, in the opinion of the investigator, may affect study&#xD;
             parameters including, but not limited to, lid margin disorders (e.g., blepharitis&#xD;
             including staphylococcal, demodex, or seborrheic; excessive lid laxity, floppy eyelid&#xD;
             syndrome, ectropion, entropion), advanced conjunctivochalasis, Salzmann's nodular&#xD;
             degeneration, and asthenopia-related conditions, allergic conjunctivitis, glaucoma,&#xD;
             diabetic retinopathy, follicular conjunctivitis, iritis, uveitis, wet-exudative&#xD;
             age-related macular degeneration, retinal vein occlusion, and/or active ocular&#xD;
             inflammation.&#xD;
&#xD;
          5. Any condition that could affect trigeminal nerve function including facial or ocular&#xD;
             Herpes Zoster/Shingle, a stroke or nerve palsy affecting the eye(s).&#xD;
&#xD;
          6. Use of any topical medication and/or antibiotics for the treatment of blepharitis or&#xD;
             meibomian gland disease in either eye within 14 days prior to Visit 2 (Day 0).&#xD;
&#xD;
          7. Active or history of ocular herpes or any other ocular infection in either eye within&#xD;
             the last 30 days prior to Visit 1 (Day -14 to Day 0).&#xD;
&#xD;
          8. Unwilling to avoid wearing contact lenses for 7 days prior to Randomization (Visit 2,&#xD;
             Day 0) and for the duration of the study period (through Visit 7, Day 98).&#xD;
&#xD;
          9. Positive urine pregnancy test at Screening, nursing an infant or planning to become&#xD;
             pregnant during the study.&#xD;
&#xD;
         10. Any blood donation or significant loss of blood within 56 days of Visit 1 (Day -14 to&#xD;
             Day 0).&#xD;
&#xD;
         11. Any history of immunodeficiency disorder, human immunodeficiency virus (HIV), positive&#xD;
             hepatitis B, C, or evidence of acute active hepatitis A (anti-hepatitis A virus&#xD;
             immunoglobulin M), or organ or bone marrow transplant.&#xD;
&#xD;
         12. Any medication (oral or topical) known to cause ocular drying that is not administered&#xD;
             as a stable dose for at least 30 days prior to Visit 1 (Day -14 to Day 0) and for the&#xD;
             duration of the study (Visit 7, Day 98); antihistamines are not allowed at any time&#xD;
             during the study.&#xD;
&#xD;
         13. Use of prohibited medications (topical, topical ophthalmic and/or systemic, during the&#xD;
             appropriate pre-study washout period (see below) and during the study. Prohibited&#xD;
             medications include topical cyclosporine or lifitegrast, use of any other ophthalmic&#xD;
             medication (e.g., glaucoma medication, topical anti-inflammatory eye drops) for the&#xD;
             duration of the study)&#xD;
&#xD;
             NOTE: Supplements containing omega-3 are allowed if the subject has been taking said&#xD;
             supplement for at least 3 months prior to Screening. Subjects are not allowed to begin&#xD;
             taking supplements containing omega-3 during the study. The appropriate pre-study&#xD;
             washout period is as follows:&#xD;
&#xD;
               1. Antihistamines (including ocular): 7 days prior to Visit 1 (Day -14 to Day 0).&#xD;
&#xD;
               2. Topical cyclosporine or lifitegrast or omega-3s within 14 days prior to Visit 1&#xD;
                  (Day -14 to Day 0).&#xD;
&#xD;
               3. Corticosteroids or mast cell stabilizers (including ocular): 14 days prior to&#xD;
                  Visit 1 (Day -14 to Day 0).&#xD;
&#xD;
               4. Depot-corticosteroids in either eye at least 45 days prior to the first dose of&#xD;
                  study drug (Day 0)&#xD;
&#xD;
               5. All other topical ophthalmic preparations (including artificial tear substitutes&#xD;
                  other than the study drops): 72 hours prior to Visit 1 (Day -14 to Day 0).&#xD;
&#xD;
               6. Introduction of any new, nonsteroidal anti-inflammatory drugs (NSAIDs) including&#xD;
                  but not limited to topical, systemic (including sleep-aids containing NSAIDs),&#xD;
                  inhaled, or irrigation solution within 7 days prior to the first dose of study&#xD;
                  drug. Subjects who are on stable dose of NSAIDs (stable for at least 4 weeks&#xD;
                  prior to the first dose of study drug) are eligible for participation and should&#xD;
                  remain on a stable dose throughout the duration of the study (i.e., through Day&#xD;
                  98).&#xD;
&#xD;
               7. Triamcinolone in either eye at least 90 days prior to the first dose of study&#xD;
                  drug (Day 0).&#xD;
&#xD;
               8. Inhaled, ingested, sublingual, transdermal or topical products containing&#xD;
                  marijuana, tetrahydrocannabinol (THC) or cannabidiol (CBD) at least 7 days prior&#xD;
                  to the first dose of study drug (Day 0).&#xD;
&#xD;
               9. Systemic pain relievers, analgesics (e.g., pregabalin, gabapentin, opioids) 14&#xD;
                  days prior to the first dose of study drug (Day 0).&#xD;
&#xD;
              10. Any supplement, prescribed medication or over-the-counter product that the&#xD;
                  investigator feels may interfere with the study parameters, including homeopathic&#xD;
                  remedies, analgesics, and pain medication.&#xD;
&#xD;
              11. Oral doxycycline within 6 months of first dose of study drug (Day 0).&#xD;
&#xD;
              12. Diuretics: Within 28 days prior to Visit 1 (Day -14 to Day -1).&#xD;
&#xD;
              13. Punctal occlusion:&#xD;
&#xD;
             i. Punctal cauterization: Randomization may not occur until 4 weeks following the&#xD;
             procedure.&#xD;
&#xD;
             ii. Permanent/semi-permanent punctal plugs (this includes 180-day punctal plugs):&#xD;
             Randomization may not occur until 4 weeks following the procedure. If a punctal plug&#xD;
             falls out during the study, it should be reinserted.&#xD;
&#xD;
             iii. Temporary collagen punctal plugs: Not permitted. If subject has a history of use&#xD;
             of temporary punctal plugs, randomization may not occur until 4 weeks since last&#xD;
             insertion and puncta are plug-free, as determined by the investigator.&#xD;
&#xD;
         14. Any significant chronic illness that, in the opinion of the investigator, could&#xD;
             interfere with the study parameters, including, but not limited to, severe&#xD;
             cardiopulmonary disease, poorly controlled hypertension, and/or poorly controlled&#xD;
             diabetes.&#xD;
&#xD;
         15. Use of any investigational product or device within 30 days prior to Visit 1 (Day -14&#xD;
             to Day 0) or during the study period.&#xD;
&#xD;
         16. History of LASIK or similar type of corneal refractive surgery within 12 months prior&#xD;
             to Visit 1 (Day -14 to Day 0), and/or any other ocular surgical procedure within 12&#xD;
             months prior to Visit 1 (Day -14 to Day 0); or any scheduled ocular surgical procedure&#xD;
             during the study period.&#xD;
&#xD;
         17. Use of any laser procedure for the eyes in the 30 days prior to Visit 1 (Day -14 to&#xD;
             Day 0).&#xD;
&#xD;
         18. Known history of alcohol and/or drug abuse within the past 12 months that in the&#xD;
             opinion of the principal investigator, may interfere with study compliance, outcome&#xD;
             measures including safety parameters, and/or the general medical condition of the&#xD;
             subject.&#xD;
&#xD;
         19. Subjects with dry eye secondary to scarring (such as that seen with irradiation,&#xD;
             alkali burns, Stevens Johnson syndrome, cicatricial pemphigoid) or destruction of&#xD;
             conjunctival goblet cells (as with vitamin A deficiency) are not eligible for the&#xD;
             study. Subjects with incidental scars secondary to refractory surgery (i.e., LASIK&#xD;
             surgery) that, in the opinion of the principal investigator, would not interfere with&#xD;
             study compliance and/or outcome measures, are not excluded from the study.&#xD;
&#xD;
         20. Subjects who test positive for the COVID-19 virus within 30 days prior to Visit 1 (Day&#xD;
             -14 to Day 0).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamran Hosseini, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Surface Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sponsor Company's Vice President of Clinical Operations</last_name>
    <phone>(925) 494-3660</phone>
    <phone_ext>18</phone_ext>
    <email>cbaenziger@surfaceophthalmics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sponsor Company's Director of Clinical Operations</last_name>
    <phone>(925) 494-3660</phone>
    <phone_ext>7</phone_ext>
    <email>kmorrison@surfaceophthalmics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cornea and Cataract Consultants of Arizona PC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Staenglen</last_name>
      <phone>602-258-4342</phone>
      <email>ccazresearch@aol.com</email>
    </contact>
    <investigator>
      <last_name>Jung Dao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canyon City EyeCare</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Beltran</last_name>
      <phone>562-225-8450</phone>
      <email>angelbeltran06@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Milton Hom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Eye Specialists</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92545</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norlisha Borntrager</last_name>
      <phone>951-492-4205</phone>
      <email>nborntrager@inlandeyespecialists.com</email>
    </contact>
    <investigator>
      <last_name>Robert Sorenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group Inc.</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Rodriguez</last_name>
      <phone>818-365-0606</phone>
      <email>rrodriguez@northvalleyeye.net</email>
    </contact>
    <investigator>
      <last_name>Robert Smyth-Medina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LoBue Laser and Eye Medical Center</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikayla Gates</last_name>
      <phone>951-696-1135</phone>
      <email>mikaylag@lobueeyecenters.com</email>
    </contact>
    <investigator>
      <last_name>Ryan Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Tyner</last_name>
      <phone>916-631-7860</phone>
      <email>heather.tyner@drwirta.com</email>
    </contact>
    <contact_backup>
      <last_name>Linda Wirta</last_name>
      <phone>916-631-7860</phone>
      <email>linda.wirta@drwirta.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Wirta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martel Eye Medical Group</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Karpach</last_name>
      <phone>916-631-7860</phone>
      <email>nataliya.marteleye@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Martel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacramento Eye Consultants, A Medical Corporation</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Phillips</last_name>
      <phone>916-649-1515</phone>
      <email>jaimep@saceye.com</email>
    </contact>
    <investigator>
      <last_name>Samuel Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Center of Northern Colorado</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Moon</last_name>
      <phone>970-419-2696</phone>
      <email>courtneym@eyecenternoco.com</email>
    </contact>
    <investigator>
      <last_name>Karl Olsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Eye Consultants, PC</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Smit</last_name>
      <phone>203-791-2020</phone>
      <phone_ext>256</phone_ext>
      <email>clinicaleye@danburyeye.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Paul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Eye Microsurgical Institute, Inc.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margo Dague</last_name>
      <phone>561-737-5500</phone>
      <email>margo@fleyedocs.com</email>
    </contact>
    <investigator>
      <last_name>Barry Schechter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hernando Eye Institute</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodelle Favot</last_name>
      <phone>352-596-4030</phone>
      <email>odelle.hernandoeye@tampabay.rr.com</email>
    </contact>
    <investigator>
      <last_name>Leonard Cacioppo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bowden Eye and Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Montogomery</last_name>
      <phone>904-296-0098</phone>
      <email>Jmontgomery@bowdeneye.com</email>
    </contact>
    <investigator>
      <last_name>Frank Bowden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Center of North Florida PA</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Menck</last_name>
      <phone>850-784-3937</phone>
      <email>eyenerdgyrl1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bret Fisher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Gallego</last_name>
      <phone>813-875-6588</phone>
      <email>Natalia@IRCTampa.com</email>
    </contact>
    <investigator>
      <last_name>Bernard Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blue Ocean Clinical Research at The Macula Center</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Miller</last_name>
      <phone>863-899-3509</phone>
      <email>dmiller@vip-us.net</email>
    </contact>
    <investigator>
      <last_name>Michael Tolentino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates, LLC</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Locke</last_name>
      <phone>770-777-1928</phone>
      <email>dlocke@craatl.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Day</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Eye</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <zip>60046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Davis</last_name>
      <phone>847-356-0700</phone>
      <email>kristen@myjacksoneye.com</email>
    </contact>
    <investigator>
      <last_name>Mitchell Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Hogeback</last_name>
      <phone>859-331-9000</phone>
      <email>khogeback@cvphealth.com</email>
    </contact>
    <investigator>
      <last_name>Edward Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentucky Eye Institute</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Karpecki, MD</last_name>
      <phone>317-334-4424</phone>
      <email>karpecki@karpecki.com</email>
    </contact>
    <investigator>
      <last_name>Paul Karpecki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Vision Research Foundation at Pepose Vision Institute</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Canter</last_name>
      <phone>636-534-5126</phone>
      <email>rcanter@midwestvrf.org</email>
    </contact>
    <investigator>
      <last_name>Mujtaba Qazi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Heftner</last_name>
      <phone>816-531-9100</phone>
      <email>mh@taubereye.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Tauber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tekwani Vision Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Dinsmore</last_name>
      <phone>314-842-2020</phone>
      <email>ldinsmore.tvc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Navin Tekwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Consultants Ltd.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Williams</last_name>
      <phone>314-646-4413</phone>
      <email>swilliams@ocstl.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Gira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EyeSight Ophthalmic Services</name>
      <address>
        <city>Somersworth</city>
        <state>New Hampshire</state>
        <zip>03878</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Shannon</last_name>
      <phone>603-501-5000</phone>
      <email>Kshannon@clearadvantagelaser.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Peters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alterman, Modi &amp; Wolter</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Piza Ortiz</last_name>
      <phone>845-454-1025</phone>
      <phone_ext>204</phone_ext>
      <email>sortiz523@aol.com</email>
    </contact>
    <investigator>
      <last_name>Satish Modi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rochester Ophthalmological Group, PC</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy VanVoorhis</last_name>
      <phone>585-244-6011</phone>
      <phone_ext>314</phone_ext>
      <email>rogstudy@rogeyecare.com</email>
    </contact>
    <investigator>
      <last_name>Paul Hartman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Physicians Protocol</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Carls</last_name>
      <phone>336-402-2500</phone>
      <email>Carls.amanda@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Karl Stonecipher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Associates, PC</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Hindman, DO</last_name>
      <phone>724-772-3000</phone>
      <email>nhindman@scottandchristie.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Zimmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bailey DeBaere</last_name>
      <phone>605-719-3153</phone>
      <email>bdebaere@bhrei.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Khachikian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, PA</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Ashe</last_name>
      <phone>901-760-4620</phone>
      <email>dashe.tec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Evans, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VRF Eye Specialty Group</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adria Dodson</last_name>
      <phone>901-685-2200</phone>
      <email>adriadodson@esg.md</email>
    </contact>
    <investigator>
      <last_name>Subba Gollamudi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West TN EyeCare dba Toyos Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Williams</last_name>
      <phone>615-327-4080</phone>
      <email>dwilliams@toyosclinic.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Toyos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texan Eye Care, PA - Keystone Research, Ltd</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Locke</last_name>
      <phone>512-541-4400</phone>
      <email>tlocke@keystoneresearch.com</email>
    </contact>
    <investigator>
      <last_name>Yen Nieman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel Belloso</last_name>
      <phone>832-553-7100</phone>
      <email>Mbelloso@Houstoneye.com</email>
    </contact>
    <investigator>
      <last_name>John Goosey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Laser Vision &amp; Surgical Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Solis</last_name>
      <phone>281-338-0425</phone>
      <email>tmsolis@intouchcrc.com</email>
    </contact>
    <investigator>
      <last_name>William Lipsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Clinics of South Texas, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Colon</last_name>
      <phone>210-826-2012</phone>
      <email>Lcolon@eyeclinicsofsouthtexas.com</email>
    </contact>
    <investigator>
      <last_name>Jay Rubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>R and R Eye Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Hazen</last_name>
      <phone>210-424-2584</phone>
      <email>maggie@eye-assoc.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Brunin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Gibb</last_name>
      <phone>801-773-4840</phone>
      <email>melanie.gibb@tannerclinic.com</email>
    </contact>
    <investigator>
      <last_name>Trent Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Institute of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Adams</last_name>
      <phone>801-263-5735</phone>
      <email>ladams@theeyeinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Randy Carter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

